Alzheimer's disease research Disease-modifying drug candidates Disease-modifying candidates in late-stage clinical trials for Alzheimer's disease

| Target_Approach | Candidate_Name | Trial_Phase | Trial_Start_Date | Expected_End_Date |
|---|---|---|---|---|
| Gamma Secretase Modulator/NSAID | MPC-7869 | Phase III | Feb 2005 | May 2008 |
| Gamma Secretase Inhibitor | LY451039 | Phase III | March 2008 | March 2012 |
| Antibody to Amyloid-Beta | aab-001 | Phase III | Dec 2007 | Dec 2010 |
| Metal-Protein Interaction Attenuation | PBT2 | Phase II (completed) | Dec 2006 | Dec 2007 |
| Fibrilization of Amyloid-Beta | AZD-103 | Phase II | Dec 2007 | May 2010 |
| Neuroprotection | AL-108 | Phase II (completed) | Jan 2007 | Jan 2008 |
| Brain Cell Apoptosis Inhibitor | Dimebon | Phase II (completed) | Sept 2006 | Nov 2007 (actual) |
| Natural Antibodies to A-Beta | IVIg | Phase II (completed) | Feb 2006 | June 2007 |
| Vaccine to Amyloid-Beta | acc-001 | Phase II | Nov 2007 | Mar 2012 |
| Notes | Notes | Notes | Notes | Notes |